BCAX (STOCKS)
Bicara Therapeutics Inc. Common Stock
$21.560000
-0.130000 (-0.60%)
Prev close: $21.690000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Claire Mazumdar
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,418.55M
- Employees
- 103
- P/E (TTM)
- -7.83
- P/B (TTM)
- 2.77
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
10
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.93 | $-0.77 | -0.1600 | -20.78% |
|
Dec 2025 (Q4)
|
$-0.68 | $-0.68 | +0.0045 | +0.66% |
|
Sep 2025 (Q3)
|
$-0.67 | $-0.56 | -0.1098 | -19.60% |
|
Jun 2025 (Q2)
|
$-0.50 | $-0.58 | +0.0799 | +13.78% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $16.94M |
| Operating Expenses | $174.06M |
| Operating Income/Loss | -$174.06M |
| Income/Loss From Continuing Operations After Tax | -$157.32M |
| Income/Loss From Continuing Operations Before Tax | -$157.12M |
| Income Tax Expense/Benefit | $197.00K |
| Net Income/Loss | -$157.32M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$157.32M |
| Net Income/Loss Available To Common Stockholders, Basic | -$157.32M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.78 |
| Diluted Earnings Per Share | -$2.78 |
| Basic Average Shares | 54,792,196,639 |
| Diluted Average Shares | 54,792,196,639 |
| Assets | $553.60M |
| Current Assets | $544.92M |
| Noncurrent Assets | $8.68M |
| Fixed Assets | $346.00K |
| Other Non-current Assets | $8.34M |
| Liabilities | $39.64M |
| Current Liabilities | $39.34M |
| Wages | $1.91M |
| Other Current Liabilities | $37.43M |
| Noncurrent Liabilities | $301.00K |
| Equity | $513.96M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $513.96M |
| Liabilities And Equity | $553.60M |
| Net Cash Flow From Operating Activities | -$116.24M |
| Net Cash Flow From Operating Activities, Continuing | -$116.24M |
| Net Cash Flow From Investing Activities | -$245.16M |
| Net Cash Flow From Investing Activities, Continuing | -$245.16M |
| Net Cash Flow From Financing Activities | $195.15M |
| Net Cash Flow From Financing Activities, Continuing | $195.15M |
| Net Cash Flow | -$166.25M |
| Net Cash Flow, Continuing | -$166.25M |
| Comprehensive Income/Loss | -$157.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$157.56M |
| Other Comprehensive Income/Loss | -$130.17M |
| Other Comprehensive Income/Loss Attributable To Parent | -$243.00K |